07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Prima, Trillium Therapeutics deal

Trillium acquired PRR's Arthron subsidiary for $500,000 in cash and 1.2 million Trillium shares, which represents a 7% stake in the company. PRR is slated to receive an additional $75,000 in cash from Trillium next...
07:00 , Oct 3, 2005 |  BC Week In Review  |  Company News

Prima, AstraZeneca deal

AZN and PRR's Arthron Pty Ltd. subsidiary extended to June 30, 2006, their 2004 deal to study Arthron's Fc receptor technology. PRR said the Fc gamma receptor IIa (CD32) is a target for autoimmune diseases,...
07:00 , Sep 12, 2005 |  BC Week In Review  |  Company News

Prima, Xencor deal

PRR's Arthron Pty Ltd. subsidiary granted to Xencor a non-exclusive two-year license to Fc receptor technology for internal research. Arthron will receive an upfront fee and an annual license fee. Xencor also received an option...
07:00 , Aug 29, 2005 |  BC Week In Review  |  Company News

Prima, Austin Research Institute deal

PRR completed its acquisition of the institute's share and option holdings in four PRR subsidiaries (see BioCentury, Aug.15). PRR now owns all shares of Oncomab Pty Ltd., Panvax Ltd., Cancer Vac Pty Ltd., and 92.5%...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Company News

Prima BioMed, Austin Research Institute deal

PRR proposed to acquire the institute's share and option holdings in four PRR subsidiaries for 15 million shares. The deal would be valued at A$1.7 million ($1.3 million) based on PRR's close of A$0.12 on...
08:00 , Nov 17, 2003 |  BC Week In Review  |  Clinical News

Prima preclinical data

PRR subsidiary Arthron Pty. Ltd. said that in a mouse model of RA, a short course of treatment with Fc receptor inhibitors caused sustained suppression of inflammation. Prima Biomed Ltd. (ASX:PRR), Melbourne, Australia   Product:...
08:00 , Oct 27, 2003 |  BC Week In Review  |  Company News

PrimaBioMed Ltd. other research news

PRR subsidiary Arthron Ltd. said that the activation of the macrophage Fc receptor triggers the release of tumor necrosis factor (TNF) alpha . Arthron is developing small molecules that inhibit the receptor. PrimaBioMed Ltd. (ASX:PRR),...